Prelude Therapeutics Incorporated (NASDAQ: PRLD) is a Healthcare company (Biotechnology) with a market capitalization of $200M. The Maz Rating grades it against the other companies in its sector.
Prelude Therapeutics Incorporated's current Maz Rating and its five factor grades are for members: log in to see them.
At $3.45, Prelude Therapeutics Incorporated trades at 8.9x sales and 2.5x book value. Over the last twelve months it generated about $22M of revenue and a net loss of $46M. It runs a gross margin of 98.3%, an operating margin of -300.6% and a net margin of -269.7%. It shows return on equity of -75.4%, return on invested capital of -43.7% and a free cash flow yield of -16.7%. On the balance sheet: a debt-to-equity ratio of 0.13 and a current ratio of 4.07. Over the past 52 weeks the share price ranged from $1.29 to $6.83, with a beta of 0.96.
Prelude Therapeutics Incorporated does not currently pay a dividend.
8 Wall Street analyst ratings cover the stock: 5 Buy, 1 Hold and 2 Sell, for a Buy consensus. This is the sell side's view, separate from the Maz Rating.
Figures are trailing twelve months unless stated. The Maz Rating and Maz Dividend Score rank a company against its own sector; they are not price targets or recommendations.